These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 22154379)

  • 41. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
    Reder AT; Ebers GC; Traboulsee A; Li D; Langdon D; Goodin DS; Bogumil T; Beckmann K; Konieczny A;
    Neurology; 2010 Jun; 74(23):1877-85. PubMed ID: 20530324
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapy with interferon-beta modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosis.
    Zaffaroni M; Marino F; Bombelli R; Rasini E; Monti M; Ferrari M; Ghezzi A; Comi G; Lecchini S; Cosentino M
    Exp Neurol; 2008 Dec; 214(2):315-21. PubMed ID: 18824168
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders.
    Carrieri PB; Ladogana P; Di Spigna G; de Leva MF; Petracca M; Montella S; Buonavolontà L; Florio C; Postiglione L
    Immunopharmacol Immunotoxicol; 2008; 30(4):1-9. PubMed ID: 18686100
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A modified immune tolerant mouse model to study the immunogenicity of recombinant human interferon beta.
    Abdolvahab MH; Brinks V; Schellekens H
    J Immunol Methods; 2014 Dec; 415():17-23. PubMed ID: 25450255
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evidence for non-enzymatic glycosylation in Escherichia coli.
    Mironova R; Niwa T; Hayashi H; Dimitrova R; Ivanov I
    Mol Microbiol; 2001 Feb; 39(4):1061-8. PubMed ID: 11251824
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glycation and post-translational processing of human interferon-gamma expressed in Escherichia coli.
    Mironova R; Niwa T; Dimitrova R; Boyanova M; Ivanov I
    J Biol Chem; 2003 Dec; 278(51):51068-74. PubMed ID: 14525998
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of patients with neutralizing antibodies against interferon-beta: stop IFN-beta therapy or wait for the antibodies to go away?
    Sorensen PS
    Eur J Neurol; 2009 Jan; 16(1):1-2. PubMed ID: 19087140
    [No Abstract]   [Full Text] [Related]  

  • 48. Stability and Activity of the Hyperglycosylated Human Interferon-β R27T Variant.
    Song K; Moon DB; Kim NY; Shin YK
    Sci Rep; 2020 May; 10(1):8412. PubMed ID: 32439982
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A genetically encoded epsilon-N-methyl lysine in mammalian cells.
    Groff D; Chen PR; Peters FB; Schultz PG
    Chembiochem; 2010 May; 11(8):1066-8. PubMed ID: 20422671
    [No Abstract]   [Full Text] [Related]  

  • 50. Factors influencing expression and post-translational modification of recombinant protein C.
    Sugiura T; Maruyama HB
    J Biotechnol; 1992 Feb; 22(3):353-60. PubMed ID: 1367989
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Specificity of the T Cell Response to Protein Biopharmaceuticals.
    Meunier S; de Bourayne M; Hamze M; Azam A; Correia E; Menier C; Maillère B
    Front Immunol; 2020; 11():1550. PubMed ID: 32793213
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of high glucose on cytokine production by human peripheral blood immune cells and type I interferon signaling in monocytes: Implications for the role of hyperglycemia in the diabetes inflammatory process and host defense against infection.
    Hu R; Xia CQ; Butfiloski E; Clare-Salzler M
    Clin Immunol; 2018 Oct; 195():139-148. PubMed ID: 29894743
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The production of cross-reactive autoantibodies that bind to bovine serum albumin in mice administered reducing sugars by subcutaneous injection.
    Park JH; Choi TS
    Cent Eur J Immunol; 2015; 40(1):25-9. PubMed ID: 26155180
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity.
    Washburn N; Schwab I; Ortiz D; Bhatnagar N; Lansing JC; Medeiros A; Tyler S; Mekala D; Cochran E; Sarvaiya H; Garofalo K; Meccariello R; Meador JW; Rutitzky L; Schultes BC; Ling L; Avery W; Nimmerjahn F; Manning AM; Kaundinya GV; Bosques CJ
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1297-306. PubMed ID: 25733881
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis.
    Link J; Lundkvist Ryner M; Fink K; Hermanrud C; Lima I; Brynedal B; Kockum I; Hillert J; Fogdell-Hahn A
    PLoS One; 2014; 9(3):e90479. PubMed ID: 24608124
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Advanced glycation end products contribute to the immunogenicity of IFN-β pharmaceuticals.
    Bozhinov A; Handzhiyski Y; Genov K; Daskalovska V; Niwa T; Ivanov I; Mironova R
    J Allergy Clin Immunol; 2012 Mar; 129(3):855-858.e6. PubMed ID: 22154379
    [No Abstract]   [Full Text] [Related]  

  • 57. Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells.
    Abdul-Ahad AK; Galazka AR; Revel M; Biffoni M; Borden EC
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):27-32. PubMed ID: 9287241
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hybrid transgenic immune tolerant mouse model for assessing the breaking of B cell tolerance by human interferon beta.
    van Beers MM; Sauerborn M; Gilli F; Hermeling S; Brinks V; Schellekens H; Jiskoot W
    J Immunol Methods; 2010 Jan; 352(1-2):32-7. PubMed ID: 19857496
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study.
    Gneiss C; Koudouovoh-Tripp PM; Ropele S; Gotwald T; Ehling R; Lutterotti A; Aichner F; Ladurner G; Eggers C; Schautzer F; Künz B; Millonig A; Aspeck E; Reindl M; Berger T; Fazekas F; Deisenhammer F
    Mult Scler; 2009 Dec; 15(12):1481-8. PubMed ID: 19965519
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis.
    Farrell RA; Giovannoni G
    Mult Scler; 2007 Jun; 13(5):567-77. PubMed ID: 17548434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.